PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 29390421
OWN - NLM
STAT- MEDLINE
DCOM- 20180213
LR  - 20180213
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 51
DP  - 2017 Dec
TI  - Comprehensive evaluation of clinical efficacy and safety of celecoxib combined
      with chemotherapy in management of gastric cancer.
PG  - e8857
LID - 10.1097/MD.0000000000008857 [doi]
AB  - BACKGROUND: To evaluate the clinical efficacy and safety of celecoxib combined
      with chemotherapy in the treatment of gastric cancer. METHODS: In total, 240
      gastric cancer patients undergoing radical gastrectomy followed by adjuvant
      chemotherapy were randomly assigned into 2 groups. In the experimental group (n =
      120), patients were administered with celecoxib-based chemotherapy, and
      chemotherapy alone was performed in the control group. Disease-free survival
      (DFS) and progression-free survival (PFS) were considered as the primary efficacy
      parameters, and objective response rate (ORR), overall survival (OS), quality of 
      life (QOL), and safety as the secondary efficacy parameters. RESULTS: The 3-year 
      OS did not significantly differ between the experimental (72%) and control groups
      (68%, P = .67). The 3-year DFS in the experimental group was 64%, which did not
      significantly differ from 51% in the control group (P = .41). In patients with
      positive cyclooxygenase-2 (COX-2) from the experimental group, the 3-year OS was 
      78%, significantly higher compared with 66% in the control group (P = .02), and
      the 3-year DFS was 70%, considerably >50% in the control group (P = .01). No
      statistical significance was identified in the incidence of nausea, neutropenia, 
      anorexia, peripheral neurotoxicity, diarrhea, vomiting, asthenia, and
      thrombocytopenia, etc. The EORTC quality of life questionnaire (QLQ)-C30
      questionnaire revealed that the global QOL in the experimental group was
      significantly higher than that in the control group (P < .05). No statistical
      significance was noted in the scores of functioning scale between 2 groups,
      whereas the scores of the symptom scale, especially pain and fatigue in the
      experimental group were remarkably higher than that in the control group (P <
      .05). The global score of EORTC QLQ-STO22 in the experimental group was
      considerably higher compared with that in the control group (P < .05). No
      statistical significance was identified in term of the domains of restrictions on
      feeding, dysphagia, anxiety, reflux, sense of taste, dry mouth, hair loss, and
      body shape between groups (all P > .05). CONCLUSION: Celecoxib combined with
      chemotherapy yields clinical benefits for gastric cancer patients with positive
      COX-2, which not only enhances the OS, DFS, PFS, QOL, and short-term clinical
      efficacy, but also does not increase the risk of adverse events.
CI  - Copyright (c) 2017 The Authors. Published by Wolters Kluwer Health, Inc. All
      rights reserved.
FAU - Guo, Qinghong
AU  - Guo Q
AD  - Department of Gastroenterology.
FAU - Liu, Xiaojun
AU  - Liu X
AD  - Department of Oncology, the First Hospital of Lanzhou University, Lanzhou.
FAU - Lu, Linzhi
AU  - Lu L
AD  - Department of Gastroenterology, Wuwei Tumor Hospital of Gansu Province, Wuwei,
      China.
FAU - Yuan, Hao
AU  - Yuan H
AD  - Department of Gastroenterology.
FAU - Wang, Yuping
AU  - Wang Y
AD  - Department of Gastroenterology.
FAU - Chen, Zhaofeng
AU  - Chen Z
AD  - Department of Gastroenterology.
FAU - Ji, Rui
AU  - Ji R
AD  - Department of Gastroenterology.
FAU - Zhou, Yongning
AU  - Zhou Y
AD  - Department of Gastroenterology.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - JCX84Q7J1L (Celecoxib)
SB  - AIM
SB  - IM
MH  - Adenocarcinoma/*drug therapy/mortality/pathology/psychology
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols
MH  - Celecoxib/administration & dosage/*therapeutic use
MH  - Chemotherapy, Adjuvant
MH  - China
MH  - Cyclooxygenase 2 Inhibitors/administration & dosage/*therapeutic use
MH  - Disease-Free Survival
MH  - Female
MH  - Gastrectomy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Quality of Life
MH  - Stomach Neoplasms/*drug therapy/mortality/pathology/psychology
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC5758123
EDAT- 2018/02/03 06:00
MHDA- 2018/02/14 06:00
CRDT- 2018/02/03 06:00
PHST- 2018/02/03 06:00 [entrez]
PHST- 2018/02/03 06:00 [pubmed]
PHST- 2018/02/14 06:00 [medline]
AID - 10.1097/MD.0000000000008857 [doi]
AID - 00005792-201712220-00008 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Dec;96(51):e8857. doi: 10.1097/MD.0000000000008857.